G Medical Innovations Holdings Ltd.
| NASDAQ: GMVD | Healthcare / Medical Devices & Instruments / - |
| 0.9100 | -0.7500 | -45.18% | Vol 14.20M | 1Y Perf -96.27% |
| Mar 31st, 2023 16:00 DELAYED |
| BID | 0.8952 | ASK | 0.9150 | ||
| Open | 2.47 | Previous Close | 1.66 | ||
| Pre-Market | - | After-Market | 0.94 | ||
| - - | 0.03 2.97% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | + 37.52 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | -1.28 | Earnings Rating | — | |
| Market Cap | 1.79M | Earnings Date | 27th Apr 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.67 | |
| Beta | -2.61 |
Today's Price Range 0.89003.13 | 52W Range 1.6257.05 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -54.04% | ||
| 1 Month | -56.87% | ||
| 3 Months | -72.26% | ||
| 6 Months | -88.82% | ||
| 1 Year | -96.27% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 164.11 | |||
ROE last 12 Months | 3.84K | |||
ROA (5Y Avg) | -122.77 | |||
ROA last 12 Months | -182.11 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -67.65 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.10 | ||||
| 5.08 | ||||
| 1.98 | ||||
| - | ||||
| -0.20 | ||||
| -38.40 | ||||
| -0.69 | ||||
| -4.19 | ||||
| 3.55M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.30 | ||||
| 0.60 | ||||
| 0.11 | ||||
| 0.87 | ||||
| -1.90 | ||||
| Leverage Ratio | -2.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -104.60 | ||||
| -354.30 | ||||
| -324.70 | ||||
| -5 272.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.22M | ||||
| 2.22 | ||||
| 28.52 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 27th Apr 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 14.20M |
| Shares Outstanding | 1.97K |
| Shares Float | 16.47M |
| Trades Count | 48.08K |
| Dollar Volume | 24.84M |
| Avg. Volume | 716.09K |
| Avg. Weekly Volume | 989.12K |
| Avg. Monthly Volume | 262.24K |
| Avg. Quarterly Volume | 896.91K |
G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) stock closed at 0.91 per share at the end of the most recent trading day (a -45.18% change compared to the prior day closing price) with a volume of 14.20M shares and market capitalization of 1.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 111 people. G Medical Innovations Holdings Ltd. CEO is Yacov Geva.
The one-year performance of G Medical Innovations Holdings Ltd. stock is -96.27%, while year-to-date (YTD) performance is -72.26%. GMVD stock has a five-year performance of %. Its 52-week range is between 1.62 and 57.05, which gives GMVD stock a 52-week price range ratio of -1.28%
G Medical Innovations Holdings Ltd. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 5.08, a price-to-sale (PS) ratio of 1.98, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -182.11%, a ROC of -67.65% and a ROE of 3 843.72%. The company’s profit margin is -%, its EBITDA margin is -324.70%, and its revenue ttm is $2.22 Million , which makes it $2.22 revenue per share.
Of the last four earnings reports from G Medical Innovations Holdings Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. G Medical Innovations Holdings Ltd.’s next earnings report date is 27th Apr 2023.
The consensus rating of Wall Street analysts for G Medical Innovations Holdings Ltd. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for G Medical Innovations Holdings Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
G Medical Innovations Holdings Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
G Medical Innovations Holdings Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 63.64, ATR14 : 0.56, CCI20 : -183.43, Chaikin Money Flow : -0.72, MACD : -0.27, Money Flow Index : 27.61, ROC : -51.08, RSI : 32.54, STOCH (14,3) : 0.89, STOCH RSI : 0.01, UO : 25.34, Williams %R : -99.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of G Medical Innovations Holdings Ltd. in the last 12-months were:
G Medical Innovations Holdings Ltd.
G Medical Innovations Holdings Ltd is a mobile health (mHealth), telemedicine solutions, and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. The company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase the quality of care, and make healthcare more personalized and precise. Its operating segment includes Products, Patient Services, and Covid-19 testing. The company generates maximum revenue from the Patient Services segment.
CEO: Yacov Geva
Telephone: +972 89584777
Address: 5 Oppenheimer Street, Rehovot 7670105, WA, IL
Number of employees: 111
